UPDATE: Teva Announces Launch of Generic Lexapro in the United States; Awarded 180-Day Period of Marketing Exclusivity

Teva Pharmaceutical Industries Ltd. TEVA announced today that it has commenced commercial launch of Escitalopram Oxalate Tablets, the Company's generic version of Forest Laboratories' depression and generalized anxiety disorder treatment, Lexapro Tablets. The brand product had annual sales of approximately $2.9 billion in the United States, based on IMS sales data. As the first company to file an Abbreviated New Drug Application containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity.